DIA’s December In Focus newsletter
Welcome to DIA’s December In Focus newsletter. This month, we review DIA’s most popular and impactful research and articles published in 2023. Enjoy reading this roadmap through our work in the life science field in 2023, and take advantage of your opportunities to learn, engage, and contribute your thought leadership through DIA in 2024.
Patient Engagement That Enables Regulatory Decisions: Co-Creating Next Steps in Patient-Focused Drug Development
This multi-purpose resource repository was designed and published to accelerate progress in patient engagement and guide follow-up conversations at DIA Europe 2023. Read in Global Forum.
Read Open Access Research from Therapeutic Innovation & Regulatory Science: Integrating Patient-Generated Health Data Throughout the Total Product Life Cycle of Medical Devices
Protecting Clinical Research, Researchers, and Research Participants in Ukraine
This article explains the importance of clinical research continuity through examples from the oncology and rare disease communities in Ukraine, as part of DIA’s March and April 2023 series on clinical research in Ukraine. Read in Global Forum.
Some Assembly Required: Solving the Puzzle of Real-World Data/Evidence
This Q&A explores the current and potential future states of real-world data and evidence from expert perspectives of both regulated industry and regulatory professionals. Read in Global Forum.
Read Open Access Research from Therapeutic Innovation & Regulatory Science: Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions
AI in Clinical Research: Defining Intelligence Shaped by Subjective Perceptions
DIA’s AI in Healthcare Community Chair introduces our December 2023 Special Section on AI in Clinical Research. Read in Global Forum.
Read Open Access Research from Therapeutic Innovation & Regulatory Science: Study on Horizon Scanning with a Focus on the Development of AI-Based Medical Products: Citation Network Analysis
Register for FREE new DIA Direct Community Webinar: De-Mystifying AI in Healthcare: Common Challenges AI Can Help Solve
DIA Research
Join the DIA Research Study on Defining Tolerability Concepts for Immuno-Oncology (I-O) Therapies Calling all industry leaders! DIA is conducting an important research study that aims to enhance our understanding of tolerability concepts in the context of I-O therapies in selected cancers and pave the way for the development of tolerability PRO instrument(s). By participating in this study, you will contribute to the advancement of tolerability in I-O therapies and ensure that patient preference is incorporated into clinical decision-making. If you are passionate about pushing boundaries and making a difference in cancer treatment, we invite funding partners to join us in this innovative work to shape the future of tolerability as an endpoint in clinical trials and research.
Breakthrough Partnership in Artificial Intelligence Research! DIA in collaboration with Tufts CSDD is thrilled to announce the partnership with 12 of the top pharma and CRO companies for an innovative research study: Examining the Current Use and ROI of Artificial Intelligence Supporting Drug Development. This unique study aims to provide insights into the application of AI in drug development, guiding companies in prioritizing investments in AI solutions. DIA still has a few slots available for funding partners.
Become a DIA Member Today
The Drug Information Association is the only global multidisciplinary organization for life science professionals, and DIA members have access to exclusive content and discounts. If you are not already a DIA member, we would like to offer you 15% off the cost of an annual membership, or 25% off a two-year membership! Simply add code MEM15 at checkout by December 31 to get the special discount. Why Join DIA:
Complimentary resources to enhance your job performance.
Professional development and networking opportunities.
DIA Communities: Interact and form cross-disciplinary teams to share common experiences and knowledge.
Access to exclusive events, conferences, and resources.